Conference abstractPublished 3 Aug 2018
Targeting therapy of hepatocarcinoma by a peptide directed doxorubicin/miRNA liposome
Shaanxi Normal University, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hepatocellular carcinoma (HCC) is a severe malignant disease to threaten human life safety, and current chemical therapeutic methods are usually developed with low efficacy and high side effects because they have no enough specific targeting to cancer cells and cannot inhibit the multiple drug resistance (MDR) of chemical therapeutics. HCSP4, a 12aa peptide was screened out in our lab using the bio-panning method from a phage displayed peptide library, and it binds to HCC cells with high specificity and sensitivity. In our study, to develop a HCC targeting chemical therapeutic delivery system with high HCC therapeutic efficacy, low side effects and satisfactory resistance for MDR, HCSP4 and miR101 were used to construct the HCC targeting DOX (doxorubicin) delivery liposome system, HCSP4-Lipo-miR101-DOX. The results in vitro showed that HCSP4-Lipo-miR101-DOX presented the much enhanced cytotoxicity to HepG2 cells and HepG2/ADR cells (DOX resistant HCC cells). To explore the mechanism by that HCSP4-Lipo-miR101-DOX presents the reversal of MDR of DOX, the expression of the genes were of the potential to be the targets of miR101 was detected with western blot. The result indicated that the expression of some genes associated with membrane transportation and cancer growth was significantly inhibited, such as ABCC5, COX-2, P-gp, VEGF, STX1A, and EZH2. The results above suggested that the HCSP4 conjugated DOX delivery system, HCSP4-Lipo -miR101-DOX is of the great promising potential to be developed as an important efficient drug system for the therapy of HCC with low recurrence, its mechanism against MDR is discussed in the study. This approach is also an important strategy can be referenced for other cancer therapeutics study.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biotechnology & Biomaterials
- SubjectBiochemistry & Biotechnology
- SubjectMaterials Science
- BylineArticles whose byline prints “Yingchun Hou”